adorable baby smiling with joy
Peds Calc

PedsCalc Pro

No ads, plus saved calculations and notes in the Pro app.

$19.99/year, about $1.67/month. Cancel anytime.

Jones Criteria Calculator for Acute Rheumatic Fever (AHA 2015)

Acute rheumatic fever is diagnosed with evidence of a preceding group A strep infection plus 2 major criteria, or 1 major and 2 minor. A recurrence can also be 3 minor. Which joint findings, fever and ESR/CRP values count depends on whether the population is low risk or moderate/high risk, so pick that first.

⚠️

Clinical disclaimer

Decision support only. Criteria vary by population risk and episode type; consult the 2015 AHA update and your institutional pathway for complete guidance, including echocardiography.
Population risk (AHA 2015)

Starts on moderate/high risk, the more inclusive criteria. Choose low risk only when the population has ARF under 2 per 100,000 school-age children a year, or rheumatic heart disease in 1 per 1,000 people or fewer.

Episode

Positive RADT/culture, elevated ASO or anti-DNase B

Major criteria
Minor criteria

How to apply the criteria

Initial episode rule: evidence of preceding group A Streptococcus (GAS) infection and either (1) two or more major criteria or (2) one major plus two or more minor criteria, interpreted in the context of population risk. The calculator tallies major/minor features and displays combinations; you remain responsible for verifying GAS evidence and risk classification.

Acute phase findings can evolve—document serial exams. Carditis may be subclinical (echo-only). Polyarthritis often migratory involving large joints. Erythema marginatum and subcutaneous nodules are uncommon but specific. Chorea can present weeks to months later and may appear isolated.

Evidence of preceding streptococcal infection

  • Positive throat culture or RADT for GAS.
  • Elevated or rising streptococcal antibody titers (e.g., ASO, anti-DNase B). A repeat titer can show a rise.

If no GAS evidence is present, reconsider the diagnosis and differentials. For isolated chorea, GAS evidence may be absent; clinical judgment and neurology/rheumatology input are key.

Major and minor criteria by population risk (AHA 2015)

Low-risk population: acute rheumatic fever incidence under 2 per 100,000 school-age children a year, or all-age rheumatic heart disease prevalence of 1 per 1,000 people a year or less. Everyone else is moderate/high risk. The calculator starts on moderate/high risk, the more inclusive criteria; switch to low risk only when the definition fits.

CriterionLow riskModerate/high risk
Major: carditisClinical and/or subclinical (echo)Clinical and/or subclinical (echo)
Major: arthritisPolyarthritis onlyMonoarthritis or polyarthritis, or polyarthralgia
Major: otherChorea, erythema marginatum, subcutaneous nodules
Minor: jointsPolyarthralgiaMonoarthralgia
Minor: fever38.5 °C or higher38 °C or higher
Minor: ESR/CRPESR 60 mm/h or more and/or CRP 3.0 mg/dL or moreESR 30 mm/h or more and/or CRP 3.0 mg/dL or more
Minor: ECGProlonged PR interval for age, unless carditis is counted as a major criterion

A joint finding counts once, as a major or a minor criterion, not both. The calculator applies both of these rules, and polyarthralgia counts as major in moderate/high-risk populations only after other causes are excluded.

Common pitfalls that delay diagnosis

  • Counting criteria before confirming low-risk versus moderate/high-risk population context.
  • Assuming normal initial echocardiogram excludes evolving carditis without planned follow-up.
  • Dismissing isolated chorea or indolent carditis because systemic findings are incomplete.
  • Failing to document secondary prophylaxis adherence history when recurrence is possible.

Recurrent ARF

Recurrent episodes have modified requirements: combinations of major/minor differ when there is prior ARF or established rheumatic heart disease. If recurrence is suspected, involve cardiology/rheumatology early and treat promptly—do not wait for all elements to declare. Secondary prophylaxis lapses (missed penicillin) raise suspicion.

  • AHA 2015: with a prior episode or established rheumatic heart disease, evidence of GAS plus 2 major, or 1 major + 2 minor, or 3 minor (after other causes are excluded).
  • Chorea alone or indolent carditis may represent recurrence even without full systemic findings.

Echocardiography, ECG, and monitoring

  • Echo is recommended for all suspected ARF to detect subclinical carditis. Repeat if initial is indeterminate or if symptoms evolve.
  • Obtain ECG (PR interval) and consider telemetry if conduction disease or heart failure symptoms.
  • Baseline labs: ESR/CRP, CBC with platelets, CMP; repeat to track inflammatory trends and to support recurrent/incomplete presentations.
  • Document murmurs carefully; regurgitant lesions (MR/AR) are common in rheumatic carditis.

Treatment and prophylaxis highlights

  • Eradicate GAS: penicillin (IM benzathine or appropriate oral course) or macrolide if true anaphylactic allergy.
  • Anti-inflammatory therapy: aspirin or naproxen for arthritis; corticosteroids may be used for severe carditis per cardiology/rheum.
  • Heart failure management as indicated (diuretics/afterload reduction) with cardiology guidance.
  • Secondary prophylaxis: long-term benzathine penicillin G (every 3–4 weeks) or oral alternatives; duration depends on presence/severity of carditis and valve disease (often years to lifelong for severe RHD).

Coordinate with cardiology and infectious diseases for regimen, duration, and patient/caregiver education. Adherence to prophylaxis is critical to prevent recurrence.

Differentials and when to escalate

  • Post-streptococcal reactive arthritis (PSRA), JIA, lupus, Lyme, serum sickness–like reactions, viral myocarditis/pericarditis, MIS-C.
  • Red flags for alternate diagnoses: septic arthritis pattern, purpuric rash, cytopenias, markedly elevated ferritin, or pericardial tamponade physiology.
  • Escalate to ID/rheum/cardiology for diagnostic uncertainty, significant carditis, or if monoarthritis is present without clear ARF features.

Caregiver communication and follow-up

  • Explain the need for GAS eradication and long-term prophylaxis to prevent recurrence and valve damage.
  • Review return precautions: worsening dyspnea, edema, syncope, chest pain, or neurologic changes.
  • Set expectations for follow-up: cardiology visits, repeat echo schedule, and adherence to prophylaxis injections or pills.
  • Provide written plans and coordinate school/daycare notes for medication schedules and activity guidance if carditis is present.

Related tools

References

FAQs

You need evidence of preceding GAS infection plus either (1) two or more major criteria or (2) one major and at least two minor criteria, interpreted in the context of population risk (low vs moderate/high).

Positive throat culture or RADT, or elevated/rising streptococcal antibodies (ASO, anti-DNase B). A murmur is evidence of carditis (a major criterion), not of strep infection, so do not count it twice.

In moderate/high-risk populations (AHA 2015), arthritis as a major criterion includes monoarthritis, polyarthritis or polyarthralgia (if other causes are excluded), and the minor criteria are monoarthralgia, fever of 38 °C or more, and ESR of 30 mm/h or more and/or CRP of 3.0 mg/dL or more. In low-risk populations only polyarthritis is major, and the minor criteria are polyarthralgia, fever of 38.5 °C or more, and ESR of 60 mm/h or more and/or CRP of 3.0 mg/dL or more.

With a prior episode of ARF or established rheumatic heart disease, a recurrence can be diagnosed with evidence of GAS plus 2 major, 1 major and 2 minor, or 3 minor criteria (AHA 2015). With 3 minor only, other likely causes should be excluded first.

Echo is recommended for all suspected ARF. Involve cardiology early for any murmurs, heart failure, conduction issues, or diagnostic uncertainty. Follow their guidance on follow-up imaging and prophylaxis.

Not reliably in evolving presentations. Repeat assessment and serial data can be necessary when clinical suspicion remains despite early nondiagnostic labs.

Include risk classification, criteria timeline, GAS evidence status, cardiac findings, and the specific decision needed from specialists. This shortens handoff delays and improves treatment clarity.